重组人血管内皮抑制素联合替吉奥胶囊治疗中晚期原发性肝癌的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 重组人血管内皮抑制素联合替吉奥胶囊治疗中晚期原发性肝癌的临床观察
TITLE:
摘要: 目的:观察重组人血管内皮抑制素联合替吉奥胶囊治疗中晚期原发性肝癌的疗效和安全性。方法:将2012年2月-2014年12月三峡大学第一临床医学院收治的94例中晚期原发性肝癌患者按随机数字表法分为联合组(48例)和对照组(46例),对照组患者每天早晚餐后30 min内口服替吉奥胶囊40~60 mg,bid;联合组患者在对照组基础上给予重组人血管内皮抑制素注射液150 mg加入0.9%氯化钠注射液210 mL中,采用便携式微量泵持续泵注120 h。治疗14 d后间隔7 d为1个周期,两组患者均治疗2个周期后评价近期客观疗效、临床受益反应(CBR)及不良反应,并比较病情进展时间和平均生存期。结果:联合组患者客观有效率为14.6%,疾病控制率为66.7%,疾病进展时间为(5.5±1.3)个月,平均生存期为(10.7±3.8)个月;对照组患者客观有效率为8.7%。疾病控制率为45.6%,疾病进展时间为(4.8±1.2)个月,平均生存期为(8.9±3.3)个月,组间比较差异均有统计学意义(P<0.05)。联合组患者总CBR率(79.2%)显著高于对照组(52.2%),差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:重组人血管内皮抑制素联合替吉奥治疗中晚期原发性肝癌可获得较好的疗效和耐受性,且不会增加不良反应发生率。
ABSTRACT: OBJECTIVE: To observe therapeutic efficacy and safety of S-1 capsules combined with recombinant human endostatin in the treatment of middle and advanced primary liver carcinoma. METHODS: Totally 94 patients with middle and advanced primary liver carcinoma in the First College of Clinical Medical Science of China Three Gorges university during Feb. 2012-Dec. 2014 were divided into combination group (48 cases) and control group (46 cases) according to random number table. Both groups were given S-1 capsules 40-60 mg orally within 30 min after breakfast and supper. Combination group additionally received Recombinant human endostatin injection 150 mg added into 0.9% Sodium chloride injection 210 mL with portable micro pump for continuous pump of 120 h. A course involved 14 d treatment and 7 d interval. Short-term objective therapeutic efficacy, clinical benefit response (CBR) and ADR were evaluated after 2 courses. Disease progression time and average survival period were compared between 2 groups. RESULTS: Objective response rate, disease control rate, disease progression time and average survival period of combination group were 14.6%, 66.7%, (5.5±1.3) months, (10.7±3.8) months; those of control group were 8.7%, 45.6%, (4.8±1.2) months, (8.9±3.3) months, with statistical significance between 2 groups (P<0.05). CBR rate of combination group(79.2%) was significantly higher than control group(52.2%), with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS: S-1 combined with recombinant human endostatin show good therapeutic efficacy and tolerance for patients with middle and advanced primary liver carcinoma, and do not increase the incidence of ADR.
期刊: 2017年第28卷第11期
作者: 苏进,史克志,刘洋,钱莹,许新华
AUTHORS: SU Jin,SHI Kezhi,LIU Yang,QIAN Ying,XU Xinhua
关键字: 替吉奥胶囊;重组人血管内皮抑制素;原发性肝癌
KEYWORDS: S-1 capsules; Recombinant human endostatin; Primary liver carcinoma
阅读数: 223 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!